Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma
Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.
Authors
- Andrew Philip Jallouk (ORCID: https://orcid.org/0000-0003-4335-7942)
- Geoffrey Shouse (ORCID: https://orcid.org/0000-0002-7917-5713)
- Robert Allyn Redd (ORCID: https://orcid.org/0000-0002-1329-5288)
- Yazeed Sawalha (ORCID: https://orcid.org/0000-0001-6355-3671)
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Steven Michael Bair (ORCID: https://orcid.org/0000-0002-0094-0014)
- Shakthi Bhaskar (ORCID: https://orcid.org/0000-0003-4528-6367)
- Allison Marie Bock (ORCID: https://orcid.org/0000-0002-3174-8877)
- Wendy Dixon
- Philippe A. Armand (ORCID: https://orcid.org/0000-0001-6098-1603)
- Karan L. Chohan (ORCID: https://orcid.org/0000-0003-1239-074X)
- Scott J. Rodig (ORCID: https://orcid.org/0000-0003-1761-9769)
- Amy A. Ayers (ORCID: https://orcid.org/0000-0003-4807-2356)
- Reid W. Merryman (ORCID: https://orcid.org/0000-0002-6360-3234)
- Ajay Major (ORCID: https://orcid.org/0000-0001-7261-1335)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Ayushi Chauhan (ORCID: https://orcid.org/0000-0003-4962-3965)
- Narendranath Epperla (ORCID: https://orcid.org/0000-0002-8216-3457)
- Gilles Andre Salles (ORCID: https://orcid.org/0000-0002-9541-8666)
- Sonia Godbole
- Jennifer Leigh Crombie (ORCID: https://orcid.org/0000-0003-3445-5129)
- Matthew Alexander Lunning (ORCID: https://orcid.org/0000-0002-2761-7612)
- Lorenzo Falchi (ORCID: https://orcid.org/0000-0003-1531-3838)
- Swetha Kambhampati Thiruvengadam
- Aaron Zou
- Pierre Stephan
- Sairah Ahmed
- Alexey V. Danilov
Institutions
- Brigham and Women's Hospital (US)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- University of Utah (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Huntsman Cancer Institute (US)
- The Ohio State University Wexner Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- University of Colorado Cancer Center (US)
- Hôpital Saint-Louis (FR)
- Dana-Farber Brigham Cancer Center (US)
- Fred and Pamela Buffett Cancer Center (US)
- University of Nebraska Medical Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Haematologica
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3324/haematol.2026.301578
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00